The hyaluronan (HA) receptor RHAMM is an important regulator of cell growth. Overexpression of RHAMM is transforming and is required for H-ras transformation. The molecular mechanism underlying growth control by RHAMM and other extracellular matrix receptors remains largely unknown. We report that soluble RHAMM induces Gz/M arrest by suppressing the expression of Cdc2/Cyclin B1, a protein kinase complex essential for mitosis. Downregulation of RHAMM by use of dominant negative mutants or antisense mRNA also decreases Cdc2 protein levels. Suppression of Cdc2 occurs as a result of an increased rate of cdc2 mRNA degradation. Moreover, tumor cells treated with soluble RHAMM are unable to form lung metastases. Thus, we show that mitosis is directly linked to RHAMM through control of Cdc2 and Cyclin B1 expression. Failure to sustain levels of Cdc2 and Cyclin B1 proteins leads to cell cycle arrest.
H
Yaluronan (HA) 1, a glycosaminoglycan (1) , is one of the matrix molecules that regulates cell locomotion via its interaction with a unique 58-70-kD cell surface receptor for HA-mediated motility, RHAMM (2) . RHAMM is constitutively overexpressed in H-ras-transformed fibroblasts (2), terminally differentiated multiple myelomas (3) , and breast carcinoma cells. It is transiently expressed in activated T cells (4) and in bovine aortic smooth muscle cells after injury (5) , coincident with cell locomotion. Polyclonal and monoclonal antibodies to RHAMM that block HA binding to RHAMM, or peptides corresponding to its HAbinding domains, completely inhibit HA-induced cell locomotion (2) (3) (4) (5) (6) . Moreover, interaction of HA with RHAMM promotes focal adhesion turnover and transient phosphorylation of focal adhesion kinase that leads to cell locomotion (7) .
In contrast to other extracellular matrix receptors, overexpression of RHAMM by transfection into nonsenescing fibroblasts results in elevated motility, anchorage-independent growth, and transformation to a fully metastatic fibrosarcoma (8) . Furthermore, mutation of the HA-binding domains in RHAMM not only destroys its ability to transform nonsenescing fibroblast, but the overexpression of this dominant negative mutant also prevents mutant H-ras 1Abbreviations used in this paper: GST, glutathione-S-transferase; HA, hyaluronan; KBG, Kentucky Bluegrass pollen; MEF, mouse embryonic fibroblast; RHAMM, receptor for hyaluronan-mediated motihty. transformation, indicating that HA:RHAMM signaling is on an essential growth regulatory pathway and downstream of ras (8) . In this report, we examined the role of RHAMM in controlling cell growth by interfering with its function either using soluble recombinant glutathione-S-transferase (GST)-RHAMM fusion protein (9) , or by suppressing its function with either a dominant negative mutant (8) or antisense RHAMM (8) . Our results suggest that RHAMM signaling controls the synthesis of Cdc2 and Cyclin B1 proteins and thus entry into mitosis.
Materials and Methods
Cell Lines. The CIR_A_S-3 (C3) cell hne is derived from a 10T1/2 fibroblast cell line transfected with the H-ras and neo R genes as described previously (10) . Mouse embryonic fibroblasts (MEFs) from 15-d-old embryos were kindly provided by Dr. Junying Yuan (Harvard Medical School, Boston, MA). Three dominant negative C3 clones (MR-C3-4D, -5B, and -5C) were derived from C3 cells stably transfected with the RHAMM cDNAs mutated in their HA-binding domains as described elsewhere (8) . Cell lines OR1 and OR2 were derived from 10T1/2 after stable transfection ofantisense RHAMM cDNA as described previously (8) . The cells were maintained in DMEM supplemented with 10% FCS. Murine mammary carcinoma cell fine FT210, which contains a temperature-sensitive mutation in Cdc2 (11), was cultured as described previously (12) .
Preparation of GST Fusion Proteins. RHAMM cDNA (2) was PCR-cloned into pGEX-2T plasmid as per the method described previously (9) . Plasmids containing GST-Kentucky Bluegrass pollen (KBG) and GST were obtained from Dr. Shyam Mohapatra (University of Manitoba). GST fusion proteins were purified from the cell lysates by affinity chromatography using glutathione agarose and eluted in 50 mM Trsi-Cl, pH 8.0, containing 5 mM glutathione as described elsewhere (9) .
Cell Cycle Analysis. Cells were harvested, fixed with 70% ethanol, treated with 2N HC1 containing 0.5% Triton X-100 at room temperature for 30 re.in, and then neutralized by treatment with 0.1 M Na2B4OT, pH 8.5. Total DNA content was detected by propidium iodide (PI) staining. The stained cells were analyzed by flow cytometry using a cell sorter (Epics model 753) and PARA1 cell cycle analysis software (both from Coulter Electronics, Inc., Hialeah, FL).
In Vitro Growth Assay. Cell density assay was carried out by seeding 5 • 104 cells in 60-ram dishes in DMEM supplemented with 10% FCS. At each point, cells were harvested by trypsinization and viable cell concentrations were determined using trypan blue exclusion.
Western Analysis. Cells were lysed in buffer containing 50 mM ~-glycerophosphate, pH 7.3, 1% NP-40, 10 mM NaF, 1% aprotinin, and 1 mM sodium vanadate (12) . The lysates were centrifuged at 30,000 g for 20 rnin at 4~ Protein concentration was determined by protein assay kit (Bio-Rad Laboratories, Richmond, CA). Lysates were loaded at equal concentrations and resolved on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes in a Tris-Cl buffer containing 25 mM Tris, 192 mM glycine, and 20% (vol/vol) methanol, pH 8.3, at 100 V for 1 h at 4~ Filters were incubated with either a 1:5,000 dilution ofpolyclonal rabbit antiserum raised against the COOH-terminal peptide (LDNQIKKM) of human Cdc2 protein (12), or 1 I.tg/ml ofpolyclonal rabbit antiserum raised against the COOHterminal domain (287-298) of human Cdk2 (Upstate Biotechnology, Inc., Lake Placid, NY), or 1 p,g/ml of monoclonal anti-human Cyclin B1 (Upstate Biotechnology, Inc.) and developed with horseradish peroxidase-conjugated goat antibody to rabbit or mouse IgG (Sigma Chemical Co., St. Louis, MO). Blotting was visualized by the enhanced chemiluminescence Western blotting system (Amersham Corp., Arlington Heights, IL) following the manufacturer's instructions.
Northern Analysis. Total cellular RNA was extracted by a rapid RNA isolation method using Trizol reagent (GIBCO BRL, Gaithersburg, MD) as per the manufacturer's instructions (13) . For half-life measurements, transcription was inhibited after addition of 20 I~g/ml actinomycin D for 2 h. RNA was isolated at different times and 20 p,g of total cellular RNA was electrophoresed through 1% formamide-agarose gels and blotted onto Nytran membranes. The blots were prehybridized and probed with random primer 32p-labeled murine cdc2 cDNA (provided by Paul Nurse, ICI~F Cell Cycle Control Laboratory, London, UK) as described previously (6) . RNA loading was determined with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. Autoradiography was analyzed by Phosphorimager SF (Molecular Dynamics, Sunnyvale, CA) using storage phosphorimaging. Nuclear run-on assay was performed as described (14) using 32p-labeled RNA to probe filter-bound cdc2 and GAPDH single strand cDNA inserts. Quantification of transcription was determined by scanning phosphorimages using Multiquant software program (Molecular Dynamics). were visually surveyed for spontaneous metastasises at the termination of the assay. For experimental metastasis assays, 4 • 105 cells were injected into the tail vein. The mice were maintained for 16-18 d, euthanized, and the lungs stained by Bouins' solution (picric acid, formaldehyde, and acetic acid [15:5:1]), and metastatic foci were counted under a dissecting microscope (10) .
Results and Discussion

Soluble R H A M M Inhibits Cell Cycle Progression. H-ras-
transformed C3 fibrosarcoma cells (10) were treated with G S T -I L H A M M and cell cycle progression was m o n i t o r e d by flow cytometry. As s h o w n in Fig. 1 A, in (Fig. 1 B) . A similar pattern o f growth inhibition was obtained with primary MEFs (Fig. 1 C) untreated cells or cells treated with GST, or GST linked to the unrelated KBG protein, expressed high levels of Cdc2. However, after R H A M M treatment, Cdc2 protein levels drastically decreased in both in C3 cells and primary MEFs, whereas Cdk2 protein levels remained unaffected (Fig. 2  A) . The suppression of Cdc2 protein was dependent on the dose (Fig. 2 B) and the length o f R H A M M treatment (Fig.  2 C) . N o significant reduction in Cdc2 protein was seen before 24 h of R H A M M treatment. Similar results were obtained when 10T1/2, R a t -l , and HeLa cells were treated with R H A M M (data not shown). Taken together, these data strongly suggest that soluble R H A M M arrests cells at G2/M by suppressing Cdc2 expression.
W e next analyzed levels o f Cyclin A and B proteins that associate with Cdc2 during entry into G2 and mitosis, respectively. In RdqAMM-treated cells, the level of Cyclin B1 dropped concomitantly with the Cdc2 protein 24 h after G S T -R H A M M treatment (Fig. 2 C) whereas the level o f Cyclin A remained unchanged (data not shown). In cycling cells, the level of Cyclin B rises in S phase, peaks at G2/M, and drops drastically at the metaphse/anaphase transition (18) , but the level of Cdc2 normally remains constant throughout the cell cycle because of its relatively long halflife (15) . The possibility that decreased levels o f Cdc2 protein may lead to premature degradation o f Cyclin B1 before anaphase was ruled out by the observation that suppression of the temperature-sensitive Cdc2 in FT210 cells (11) at restrictive temperature did not alter Cychn B1 expression (Fig. 2 C-) . These results suggest that treatment with soluble R H A M M leads to suppression o f Cdc2 as well as its mitotic partner Cyclin B1.
To establish whether R H A M M signaling is essential for progression through G2/M, we examined Cdc2 protein levels in several C3 fibrosarcoma cell clones that express R H A M M mutated in the H A -b i n d i n g domains that acts as a dominant suppressor (8) . These C3 clones, M R -C 3 -4 D , -5B, and -5C, resemble nontransformed fibroblasts in their reduced growth rate and are nontumorigenic despite expressing high levels o f H-ras (8) . Cdc2 protein levels were examined in cells arrested at G2/M by nocodazole and, as shown in Fig. 2 D, resistant to H-ras transformation (8), also have reduced Cdc2 protein levels (Fig. 2 E) . Taken together, these results indicate that HA:RHAMM-mediated signaling is necessary for maintenance of Cdc2 protein levels. Soluble RHAMM Increases cdc2 mRNA Degradation Rate. In cycling cells, Cdc2 protein levels are maintained at a nearly constant steady-state level, however cdc2 mRNA synthesis is initiated during each cell cycle beginning at the G1/S transition reaching a maximum at G2 (19, 20) . As shown in Fig. 3 A, an increase in cdc2 mRNA levels was seen in control C3 cells after serum stimulation. However, 5 h after treatment with RHAMM in the presence of serum, cdc2 mRNA levels of C3 cells decreased, and by 17-24 h of treatment, a greater than 10-fold reduction was seen. Nuclear run-on assays performed with C3 nuclei prepared from cells cultured in the presence or absence of RHAMM revealed no change in transcription of cdc2 mRNA that could account for the reduced levels (Fig. 3  B) . To explore the alternative possibility that RHAMM alters cdc2 mRNA degradation rates, we next determined the mRNA half-life by examining RNA levels over time after treatment of C3 cells with actinomycin D. In the presence of RHAMM, the cdc2 mRNA half-life was reduced to 4.5-5 h from the normal 15 h (Fig. 3, C and D) . These results indicate that soluble RHAMM suppressed Cdc2 protein and RNA expression by increasing the degradation rate of cdc2 mRNA.
Soluble RHAMM Inhibits Tumorigenicity and Metastasis. We have previously shown that HA:RHAMM signaling is essential for H-ras transformation (8) . In the present study we wanted to determine if suppression of signaling induced by soluble RHAMM reduced the tumorigenicity and metastatic ability of C3 fibrosarcomas (10) . Mice receiving 3 • 105 viable cells subcutaneously after treatment with RHAMM for 48 h in vitro developed subcutaneous tumors that were smaller and appeared later than controls, and no spontaneous metastases were observed in these mice (Table 1) . Moreover, after intravenous injection, RHAMMtreated cells formed very few lung nodules (10/lung) compared with both control groups (>300/lung). These results suggest that soluble RHAMM can suppress receptor signaling and tumorigenicity similar to altering receptor function (8) . It is also possible that tumor cells that were treated with soluble RHAMM failed either to migrate through extracellular matrix or to interact with HA at a distant site, and thus inhibited metastasis. A similar approach has been used for CD44, another HA receptor, in which infusion of soluble CD44H-Ig fusion protein inhibited metastasis (21, 22) .
Our study indicates that RHAMM signaling may coordinately regulate the synthesis of Cdc2 and the detachment required for cells to enter mitosis. The synthesis of HA, which is the RHAMM ligand, has been correlated to many cellular functions including cell proliferation and cell division (1). In particular, HA synthesis and synthase activity increase during mitosis when cells round and are loosely adherent, possibly because HA is required for detachment of cells from the supporting matrix (23) . Synergistic interactions between growth factors and integrin-mediated signal transduction involving sustained tyrosine phosphorylation regulate cell proliferation and cell adhesion during G 1 to S transition (24) (25) (26) (27) and Cyclin A expression has been shown to be a target for adhesion-dependent signals (28) . In contrast, HA:RHAMM interactions that involve rapid but transient tyrosine phosphorylation and promote deadhesion (7) may be required specifically during G2/M transition where increased HA synthesis occurs (23) . Thus, Cdc2 seems to be a target of RHAMM-mediated signaling events at mitosis. Whether Cyclin B1 is directly suppressed by RHAMM or occurs secondary to suppression of Cdc2 remains to be elucidated.
